India  

Dr. Reddy's Laboratories

Indian multinational pharmaceutical company

Dr. Reddy's Laboratories    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.

0
shares
ShareTweetSavePostSend
 

You Might Like


Panacea Biotec to manufacture up to 25 million doses of Sputnik V vaccine

The company has entered into a "licensing and manufacturing agreement with Human Vaccine Limited Liability Company, a subsidiary of Russian Direct Investment Fund, Russia, Generium Joint Stock..
IndiaTimes - Published

'Will strengthen commercial roll-out of Sputnik V vaccine in India in coming weeks', assures Dr Reddy's Laboratories

"We will strengthen the commercial roll-out of Sputnik V in the coming weeks. Neither the ongoing soft commercial launch nor work towards its ramp-up in India has been put on hold," said Dr Reddy's..
IndiaTimes - Published

In a first, 5 Indian pharma majors ally for Covid drug trials

In a first, five Indian pharma majors have joined hands to conduct phase-III clinical trials of investigational anti-viral drug Molnupiravir on mild Covid-19 patients. The companies include Dr Reddy's..
IndiaTimes - Published

COVID-19: Serum Institute applies to DCGI to manufacture Sputnik V vaccine in India

Pune-based Serum Institute has also sought approval for test analysis and examination. Sputnik V is currently being manufactured by Dr Reddy's Lab.
DNA - Published

COVID-19 vaccine: 'Sputnik V' to be available in Delhi after June 20, says Kejriwal

The Delhi Government has been in talks with Dr Reddy's Laboratories for the supply of the 'Sputnik V' vaccine.
DNA - Published

Not authorised any 3rd party to supply Sputnik V in India, legal action against unscrupulous elements: Dr Reddy’s & RDIF


IndiaTimes - Published

Dr Reddy's developing new treatment options for Covid-19, says MD

Drug major Dr Reddy's Laboratories is working on the development of new treatment options for Covid-19 patients which it aims to launch over the next few months while ensuring uninterrupted supplies of..
IndiaTimes - Published

DRDO's 2-DG anti-Covid drug to be available by mid-June: Dr Reddy's

Dr Reddy's on Wednesday said that the supply of anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) is expected to commence in mid-June. In a..
IndiaTimes - Published

Rajnath Singh to release first batch of DRDO's anti-COVID oral drug 2DG today

Developed by DRDO's INMAS, in collaboration with Dr Reddy's Laboratories in Hyderabad, the 2DG drug is an anti-Covid therapeutic application.
DNA - Published

Dr Reddy's rolls out Sputnik V Covid-19 vaccine in India at around Rs 995 per dose

Dr Reddy’s Laboratories, the Indian partner of Russian Direct Investment Fund (RDIF), said it has commenced Sputnik V’s India rollout with the first dose being administered in Hyderabad on Friday..
IndiaTimes - Published

As India eyes Sputnik rollout, experts question efficacy data

Even as India is gearing up to roll out Russian Covid-19 vaccine Sputnik V next week, a group of international experts has raised serious questions about the data discrepancies and substandard..
IndiaTimes - Published

Potential cancer drug repurposed for Covid-19 by DRDO, Dr Reddy's gets DCGI nod for emergency use

A potential cancer drug repurposed for Covid-19 treatment -- 2-deoxy-D-glucose (2-DG) – has received the Drugs Controller General of India (DCGI) nod for emergency use as adjunct therapy for..
IndiaTimes - Published

Sputnik V cleared for launch in India: Five things you need to know about Russian Covid-19 vaccine

Dr Reddy's Laboratories said on Tuesday it has received permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations...
IndiaTimes - Published

Expert panel seeks additional data from Dr Reddy's Laboratories on Russian Covid vaccine Sputnik V


IndiaTimes - Published

Dr Reddy's initiates process for emergency use authorisation of Sputnik V

Dr Reddy's Laboratories said on Friday it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation of human adenoviral vector-based platform vaccine..
IndiaTimes - Published

Sputnik V India rollout in emergency use authorisation mode expected in March

The Russian Covid-19 vaccine Sputnik V is expected to be rolled out into the Indian market in March this year in EUA (emergency use authorisation) mode, a top official of Dr Reddy’s Laboratories said..
IndiaTimes - Published

All Indian vaccines being developed for storage at 2-8 degree Celsius: DBT secretary

Swarup said Dr Reddy's Laboratories has partnered with Russia's Gamaleya Institute and a vaccine is being developed for India targeting storage at 2-8 degrees Celsius. The country's drugs regulator..
IndiaTimes - Published

Russia will jointly produce Sputnik V vaccine with India: Envoy

Russian envoy in New Delhi Nikolay Kudashev on Monday said Moscow will jointly produce the Sputnik V vaccine for Covid-19 along with India and it will be manufactured by Indian pharma major Dr Reddy's..
IndiaTimes - Published

Dr Reddy's, RDIF begin clinical trials for Russia's Sputnik V vaccine in India

Dr Reddy's and RDIF had entered into a partnership to conduct clinical trials and rights for distribution of the first 100 million doses in India.
DNA - Published

India trials of Russian Sputnik-V vaccine may end as early as March: Dr Reddy's

The company expects to enrol 100 participants for the mid-stage trial and 1,500 people for the late-stage.
DNA - Published Also reported by •IndiaTimes

Russian Sputnik V Covid-19 vaccine to be tested on 100 Indian volunteers

The Russian Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General (DCGI) told Sputnik on..
IndiaTimes - Published

Dr Reddy's gets DCGI go-ahead to conduct Phase 2/3 human trials of Sputnik V in India

After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian Covid-19 vaccine Sputnik V, the company..
IndiaTimes - Published

India declines proposal to test Sputnik-V Covid-19 vaccine in large study

India's drug regulator has knocked back a proposal from Dr Reddy's Laboratories Ltd to conduct a large study in the country to evaluate Russia's Sputnik-V Covid-19 vaccine and has asked it to first..
IndiaTimes - Published

COVID-19 vaccine to be available in India by early 2021: Union Health Minister Harsh Vardhan

Meanwhile, Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of the world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds..
DNA - Published

Russia, Dr Reddy’s tie up for Sputnik V trial

Russia’s sovereign wealth fund – Russian Direct Investment Fund (RDIF) — has partnered Hyderabad-based drug maker Dr Reddy’s Laboratories to cooperate on clinical trials and distribution of..
IndiaTimes - Published

Russia confirms deal with Dr. Reddy's for COVID-19 vaccine 'Sputnik V' trials in India, to supply 100 million doses

Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds up plans to..
DNA - Published

Russia to sell 100 million doses of Covid-19 vaccine to India

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against Covid-19 once it receives regulatory approval...
IndiaTimes - Published